Arm FY2025 valuation: strong growth, thin free cash flow and a high P/E
Arm’s latest fully comparable period is FY2025, ended March 31, 2025: revenue was about $4.007 billion, net income was about $792 million, and Q4 FYE25 revenue reached $1.241 billion, up 34% year over year.[2][4][6] The valuation already embeds high expectations: Twelve Data lists Arm’s trailing P/E at 192.96x, forw...
ARM FY2025財務數據與估值假設：營收、FCF、PE、WACC怎麼看ARM FY2025數據顯示成長與高估值並存；估值模型需把現金流和資料口徑納入敏感度分析。
AI Prompt
Create a landscape editorial hero image for this Studio Global article: ARM FY2025財務數據與估值假設：營收、FCF、PE、WACC怎麼看. Article summary: ARM在提供資料中最新可核實完整期間是FY2025／Q4 FYE25（截至2025 03 31），TTM營收約40.1億美元、Q4營收12.41億美元；但總負債、完整5年CAGR、同行PE資料不足，WACC與1–5年成長率只能作為估值情境。[2][4]. Topic tags: arm holdings, semiconductors, chip design, ai chips, stocks. Reference image context from search candidates: Reference image 1: visual subject "A financial projection chart for Arm Holdings plc shows an estimated stock price increase from $124.61 to a target of $201.16, with projected revenue growth of around 20.8% over th" Reference image 2: visual subject "A financial analysis table presents ARM Holdings' valuation assumptions, including current stock price, target price, potential total return of +158.7%, and a forecasted stock pric" Style: premium digital editorial illustration, source-backed research mood, clean composi
openai.com
Arm’s FY2025 valuation question is not whether the company is growing. The evidence says it is. The harder question is whether that growth can convert into enough free cash flow to support a market multiple that is already very high.
The available data show strong FY2025 revenue and net income growth, a net cash profile, and powerful near-term momentum. They also show a relatively low free cash flow figure affected by working-capital movements, plus gaps in the data needed for a clean five-year CAGR or full peer-average comparison.
That makes scenario analysis more useful than a single headline DCF value.
First, define the period: FY2025 is not calendar Q4 2025
Arm’s relevant period here is fiscal year 2025, not the fourth quarter of the 2025 calendar year. Twelve Data lists Arm’s fiscal year end and most recent quarter as March 31, 2025. Arm’s investor presentation uses the “Q4 FYE25” label and reports total revenue of $1.241 billion for that fiscal fourth quarter, up 34% year over year.
Studio Global AI
Search, cite, and publish your own answer
Use this topic as a starting point for a fresh source-backed answer, then compare citations before you share it.
What is the short answer to "Arm FY2025 valuation: strong growth, thin free cash flow and a high P/E"?
Arm’s latest fully comparable period is FY2025, ended March 31, 2025: revenue was about $4.007 billion, net income was about $792 million, and Q4 FYE25 revenue reached $1.241 billion, up 34% year over year.[2][4][6]
What are the key points to validate first?
Arm’s latest fully comparable period is FY2025, ended March 31, 2025: revenue was about $4.007 billion, net income was about $792 million, and Q4 FYE25 revenue reached $1.241 billion, up 34% year over year.[2][4][6] The valuation already embeds high expectations: Twelve Data lists Arm’s trailing P/E at 192.96x, forward P/E at 70.25x and price to sales ratio at 38.26x.[4]
What should I do next in practice?
A balanced DCF should use scenarios rather than a single answer. A neutral starting point could use a 10%–11% WACC, 15%–20% five year revenue CAGR and 3.0%–3.5% terminal growth rate, while closely testing free cash fl...
So in this analysis, “Q4 FYE25” means the fiscal quarter ended March 31, 2025.
Key FY2025 and TTM numbers
Metric
Latest available figure
Valuation read-through
Revenue
TTM revenue of about $4.01 billion; FY2025 revenue of $4.007 billion
Twelve Data lists revenue TTM at $4.01 billion, while USFINIQ lists FY2025 revenue at $4.007 billion.
Q4 FYE25 revenue
$1.241 billion, up 34% year over year
Strong short-term momentum, but not a rate to automatically extrapolate indefinitely.
FY2025 revenue growth
Roughly 23.9%–24.1%, with a source discrepancy
USFINIQ lists FY2025 revenue of $4.007 billion versus FY2024 revenue of $3.233 billion, which implies about 23.9% growth, and its text says 24.1%; Architecting IT also lists FY2025 revenue at $4.007 billion but describes full-year growth as 20.6%.
Net income
About $792 million
Twelve Data lists net income to common TTM at $792 million; USFINIQ also lists FY2025 net income at $792 million.
Free cash flow
About $178 million
StockTitan lists free cash flow at $178 million, operating cash flow at $397 million and capital spending at $219 million; Arm’s investor presentation says FYE25 TTM free cash flow was negatively affected by a reversal of a prior working-capital benefit.
Cash and net debt
Total cash MRQ of $2.82 billion; net debt of negative $1.729 billion
This supports a net cash interpretation, but it is not a full debt schedule or a breakdown of cash and short-term investments.
Arm is priced like a high-growth stock, which raises the importance of future earnings and free cash flow execution.
Growth is strong, but one year is not a five-year CAGR
The cleanest growth comparison in the available data is FY2024 to FY2025. USFINIQ lists FY2024 revenue at $3.233 billion and FY2025 revenue at $4.007 billion, which implies about 23.9% year-over-year growth; the same source describes FY2025 revenue growth as 24.1%.
USFINIQ also lists FY2025 net income at $792 million versus $306 million in FY2024, and describes net income growth as 159.8%. That supports the view that Arm’s recent growth has been strong.
But it does not support a precise five-year CAGR. The provided sources do not include a complete five-year sequence for revenue, EPS, net income and free cash flow. For a valuation model, that matters: a one-year growth rate should not be used as a substitute for a full long-term growth record.
Peer comparisons also need care. CSIMarket says Arm’s revenue grew 23.94% in the fourth quarter of 2025 and that semiconductor industry revenue grew 26.21%; Arm’s own investor presentation says Q4 FYE25 total revenue grew 34% year over year. Those figures may reflect different period definitions or data conventions, so they should not be turned into a sweeping long-term industry conclusion.
Free cash flow is the main swing factor
StockTitan lists Arm’s free cash flow at $178 million, well below FY2025 revenue of $4.007 billion. As a rough cross-check, that puts free cash flow at about 4.4% of revenue.
The same StockTitan data list operating cash flow at $397 million, capital spending at $219 million and receivables rising to $1.1 billion. That points to cash conversion as a key issue for valuation.
This does not necessarily mean Arm’s long-term cash generation has deteriorated. Arm’s investor presentation says FYE25 trailing-twelve-month free cash flow was negatively affected by the reversal of a Q4 FYE24 working-capital benefit related to awards vesting after the IPO.
Still, for a high-multiple stock, investors need more than revenue growth. They need evidence that revenue and accounting profit can turn into repeatable free cash flow.
The P/E is already pricing in a lot
Twelve Data lists Arm’s trailing P/E at 192.96x, forward P/E at 70.25x and price-to-sales ratio at 38.26x. CSIMarket also says Arm’s current trailing-twelve-month P/E is above the semiconductor industry average, although the provided excerpt does not give the industry-average P/E number.
That supports a cautious conclusion: Arm is a high-expectation stock. But without a complete peer table for P/E, PEG, margins and growth rates, it would be misleading to invent a competitor average.
The practical implication is simple: if earnings or free cash flow fall short, the valuation has less room for disappointment.
WACC: use scenarios, not false precision
A precise WACC calculation normally requires beta, cost of equity, after-tax cost of debt, tax assumptions and a full capital structure. The provided sources do not supply all of those inputs. A better approach is to build sensitivity cases around the discount rate, revenue growth and terminal growth rate.
Scenario
WACC assumption
Year 1–5 revenue CAGR assumption
Terminal growth assumption
When it fits
Conservative
11%–12%
10%–15%
2.5%–3.0%
Useful if you want to reflect low free cash flow conversion, incomplete long-term data and high valuation risk; StockTitan lists free cash flow at $178 million.
Base case
10%–11%
15%–20%
3.0%–3.5%
Starts from FY2025 revenue growth of roughly 24%, but assumes growth gradually normalises.
Bull case
9%–10%
20%–25%
3.5%–4.0%
Requires Q4 FYE25’s 34% revenue growth momentum to continue for longer and cash conversion to improve.
These are DCF modelling inputs, not Arm guidance and not market consensus. If the model is highly sensitive to terminal value, the first things to check are whether the terminal growth rate is too high and whether the free cash flow margin assumption is too optimistic.
A practical base-case revenue path
For a neutral model, it is more reasonable to fade growth over time than to assume FY2025 or Q4 FYE25 growth continues forever. FY2025 revenue was about $4.007 billion, while Q4 FYE25 revenue was $1.241 billion and up 34% year over year.
Forecast period
Revenue growth assumption
Valuation rationale
Year 1
20%–25%
Close to FY2025’s roughly 24% revenue growth, but below the 34% growth reported for Q4 FYE25.
Year 2
18%–23%
Assumes licensing and royalty demand remain strong, while the higher base starts to slow growth.
Year 3
15%–20%
Still high growth, but moving toward a more sustainable range.
Year 4
12%–17%
If the forward P/E remains around 70.25x, the market will likely expect earnings and cash flow to improve alongside revenue.
Year 5
10%–15%
Assumes Arm’s larger revenue base gradually reduces the growth rate.
Terminal period
3%–4%
Best treated as a sensitivity range rather than a claim that high growth lasts forever.
What should not be treated as precisely known
Cash and short-term investments: Twelve Data verifies total cash MRQ of $2.82 billion, but the provided sources do not break out short-term investments.
Total liabilities or total debt: USFINIQ lists net debt at negative $1.729 billion, which indicates a net cash position under its methodology, but net debt is not the same as total liabilities or a detailed debt schedule.
Five-year CAGR: The provided data do not include a full five-year financial sequence, so FY2025’s one-year growth rate should not be used as a five-year CAGR.
Industry and peer averages: The sources provide limited quarterly and valuation context, and the CSIMarket growth figure does not line up exactly with Arm’s Q4 FYE25 investor-presentation figure.
FY2025 revenue growth rate: The same FY2025 revenue figure of $4.007 billion appears alongside different growth descriptions: 20.6% in Architecting IT and roughly 24% in USFINIQ’s data and text.
Bottom line
Arm’s FY2025 numbers support the view that the business is growing quickly: FY2025 revenue was about $4.007 billion, net income was about $792 million, and Q4 FYE25 revenue reached $1.241 billion, up 34% year over year.
But the stock’s valuation is demanding. Twelve Data lists a trailing P/E of 192.96x and a forward P/E of 70.25x, while StockTitan lists free cash flow at $178 million.
A balanced valuation framework would start with a neutral DCF case: WACC of 10%–11%, five-year revenue CAGR of 15%–20%, and terminal growth of 3.0%–3.5%. If free cash flow fails to scale with revenue and net income, the model should use a higher discount rate or lower terminal value. If cash conversion improves meaningfully, then a more optimistic growth-and-WACC combination becomes easier to test.
Comments
0 comments